Why is Jefferies bullish on the Ampol (ASX:ALD) share price?

We take a look at what one broker has to say about the petroleum giant's stock

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ampol Limited (ASX: ALD) share price is inching higher today, up 0.86% to $28.08 at the time of writing.

It's been a difficult period for the petroleum giant these past 3 months, with shares trading as high as $31.95 in November before retracing backward to their current levels.

Add in that shares are trending in a sideways channel over the last 12 months, and the recipe is becoming more and more flavourless for Ampol shareholders.

So with these points in mind, we ask, is Ampol a buy? Let's take a closer look at what the experts are saying.

Concept image of a businessman riding a bull on an upwards arrow.

Image source: Getty Images

What's Jefferies saying about Ampol?

The team at investment bank Jefferies notes that Viva Energy Group Ltd (ASX: VEA)'s recent upgrade to earnings guidance bodes well for Ampol.

Jefferies points out that Ampol is Viva's major competitor in the Australian petroleum refining and marketing segment. As a result, any upgrade to Viva's earnings outlook transposes as a positive catalyst to Ampol.

In a recent note, Viva advised it expects earnings before interest, taxes, depreciation, and amortisation (EBITDA) to come in at $470 million to $490 million in 2021, which is a substantial jump of almost 20% from median Jefferies forecasts.

The broker notes that Viva's upgrade was likely due to margin performance at the refining and retail segments. While it acknowledges that "Viva is likely outperforming in both commercial and retail", it concurrently believes "these dynamics augur in well for Ampol".

Jefferies says it "remains positive on both stocks given leverage to COVID recovery and attractive valuations". For reference, Ampol is currently trading at 14.6x price to earnings (P/E) and just under 2.3x price to book (P/B).

The team at Barrenjoey Capital Markets recently upgraded its rating on Ampol as well, recommending it as overweight with a $36.68 valuation.

This sentiment appears to be shared with the majority of analysts covering Ampol, according to Bloomberg Intelligence.

From the list of analysts covering Ampol almost 60% reckon it is a buy right now, with a consensus price target of $33.74. This consensus valuation offers a 12-month return potential of around 20% from the current market price.

What are other analysts saying about the Ampol share price?

With respect to some specific valuations, Credit Suisse has Ampol as neutral at a price target of $29.53, whereas Morgan Stanley likes the shares and rates Ampol as a buy at a $35 per share valuation.

RBC Capital Markets holds the same view and rates Ampol a buy with a $33 per share price target. In contrast, Barclay Pearce isn't as rosy and reckons the company is a hold at $24.91 per share.

The number of analysts covering Ampol and rating it a buy has crept down gradually over the last 12 months.

This downward move has occurred alongside the Ampol share price, which has also slipped around 1.5% into the red in that same time.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: What this leading broker is saying about Lynas shares

Is it bullish or bearish? Let's find out.

Read more »

share buyers, investors, happy investors
Broker Notes

Bell Potter's top ASX 200 holdings revealed

These are the top holdings in the broker's core portfolio.

Read more »

An athlete runs fast with a trail of yellow smoke billowing out behind him.
Broker Notes

Up 139% in a year, why this buy rated ASX All Ords rare earths stock could keep racing higher

A leading broker forecasts more outperformance to come from this surging ASX rare earths stock.

Read more »

Miner with thumbs up at a mine.
Gold

2 ASX gold miners to buy for solid share price gains, according to Barrenjoey

The Africa-focused companies are deeply undervalued after recent sell-offs, the broker says.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »